Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606492 | 0.89 | LMNA (0.52) | LMNAMAPTTHRBDRD2MMP13 | |
| SCHEMBL6605355 | 0.88 | LMNA (0.51) | LMNAMAPTRAB9ATHRBSMN1; SMN2 | |
| SCHEMBL6609494 | 0.87 | LMNA (0.51) | LMNAMAPTRAB9ATHRBSMN1; SMN2 | |
| SCHEMBL6607095 | 0.85 | LMNA (0.49) | LMNAMAPTRAB9ATHRBSMN1; SMN2 | |
| SCHEMBL6470981 | 0.84 | LMNA (0.47) | LMNAMAPTTHRBSMN1; SMN2 | |
| SCHEMBL6607569 | 0.82 | LMNA (0.48) | LMNAMAPTRAB9ATHRBSMN1; SMN2 | |
| SCHEMBL6609056 | 0.82 | XDH (0.51) | LMNAMAPTTHRBGAADRD2 | |
| SCHEMBL6607141 | 0.81 | MMP13 (0.53) | LMNAMAPTTHRBGAADRD2 | |
| SCHEMBL6512902 | 0.81 | ALDH1A1 (0.53) | MAPTGAASMN1; SMN2DRD2ALDH1A1 | |
| SCHEMBL6605189 | 0.81 | MMP13 (0.60) | LMNAMAPTTHRBMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| EP-1368327-B1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| EP-1368327-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6656932-B2 | Treating osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure | WARNER-LAMBERT COMPANY | 2003-12-02 | — | — | US | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| WO-2002064578-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | LMNA 2113/4885MAPT 2826/4885RAB9A 3944/4885 |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | LMNA 3858/4885MAPT 4336/4885RAB9A 2412/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | LMNA 1627/4885MAPT 2607/4885RAB9A 3808/4885 |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP11, MMP13, MMP10 | LMNA 4332/4885MAPT 1438/4885RAB9A 2332/4885 |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP11, MMP13, MMP10 | LMNA 4131/4885MAPT 1677/4885RAB9A 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.